Eternity in Medical Information -- Medisurf
Items 1 ~ 8 of 28, Page 1 of 4
IBM, KPMG, Merck and Walmart to collaborate as part of FDA’s program to evaluate the use of blockchain to protect pharmaceutical product integrity
The FDA pilot program explores innovative and emerging approaches for the tracing and verification of prescription products
06.13.2019 MERCK
Current Legal Cannabis Driving Limits in U.S., Europe Are Ineffective According to Breaking Research in AACC뭩 Clinical Chemistry Journal
New findings, published today in AACC뭩 Clinical Chemistry journal, add to a growing body of evidence suggesting that no legal driving limit for cannabis can catch impaired recreational users without unfairly penalizing unimpaired regular or medicinal users.
05.14.2019 AACC
Statement from Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research, on FDA’s continued confidence in the safety and effectiveness of the measles, mumps, and rubella (MMR) vaccine
04.22.2019 U.S. FOOD & DRUG ADMINISTRATION
FDA approves first generic naloxone nasal spray to treat opioid overdose
Agency is also taking new steps to support development of over-the-counter and additional generics of naloxone to help reduce opioid overdose deaths, increase access to emergency treatment
04.19.2019 U.S. FOOD & DRUG ADMINISTRATION
FDA orders important safety labeling changes for Addyi
04.11.2019 U.S. FOOD & DRUG ADMINISTRATION
Statement on FDA’s ongoing scientific investigation of potential safety issue related to seizures reported following e-cigarette use, particularly in youth and young adults
04.03.2019 U.S. FOOD & DRUG ADMINISTRATION
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products
03.07.2019 U.S. FOOD & DRUG ADMINISTRATION
FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall
The U.S. Food and Drug Administration is updating the public on the agency’s ongoing investigation surrounding the recent voluntary recalls of multiple generic angiotensin II receptor blocker (ARB) drug products used to treat high blood pressure and heart failure.
03.01.2019 U.S. FOOD & DRUG ADMINISTRATION
   
1 2 3 4